A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.
第一作者:
C,Gong
第一单位:
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
作者:
医学主题词
人类(Humans);脱氧胞苷(Deoxycytidine);女(雌)性(Female);顺铂(Cisplatin);卡铂(Carboplatin);中年人(Middle Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);成年人(Adult);老年人(Aged);前瞻性研究(Prospective Studies);肿瘤转移(Neoplasm Metastasis)
DOI
10.1016/j.esmoop.2026.106889
PMID
41861752
发布时间
2026-04-22
- 浏览1
ESMO open
2026年11卷4期
106889页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



